HUM00189911 O	ptimization of TEA Modalities fo	or Treatment of IBS-C
Visit # (A-E)	SUBJECT ID: 1001	VISIT DATE: 8 724, 21
DATE INFOMRED	CONSENT SIGNED://	Drawing Code:
Demographics	<u>5</u>	
Sex: □ M □ F	Year of birth: Height: _	ft in Weight: lbs
Race: □White □Black or African	American or Other Pacific Islander	Ethnicity:  □Hispanic or Latino □Not Hispanic or Latino □Unknown
Initials and Date:		
Eligibility Crite	eria	
Inclusion Criteria: of the following cr		ate in this study, a study participant must meet <u>all</u>
□ Yes □ No	Male or female, aged 18 to 99	)
□ Yes □ No	Willing to comply with all stud	ly procedures and be available for the duration of
□ Yes □ No	Diagnosed with IBS-C satisfyin	ng Rome IV criteria (Survey completed by subject)
□ Yes □ No	Have symptoms present for a	t least the last 3 months
□ Yes □ No	Have abdominal pain that is n and the time of randomization	ot adequately relieved at the time of screening
□ Yes □ No	Has a VAS pain score of >3 (or	n 0-10 score)

Rome IV Criteria	for IBS		
	inal pain on average at leas	st 1 day/week in the	□ Yes □ No
last 3 months rela	ated to defecation.		
		-1.1.4/	□ Yes □ No
Recurrent abdom	inal pain on average at leas	st I day/week in the	□ Yes □ NO
last 3 months ass	ociated with a change in fre	equency of stool.	
Recurrent abdom	ninal pain on average at leas	st 1 day/week in the	□ Yes □ No
	ociated with a change in fo		
stool.			
		- Laurence	
	A potential study participant		ollowing exclusion criteria at
baseline will be ex	cluded from participation in th	nis study it:	
□ Yes □ No	Have an unrelated active d	isorder which may invol	ve abdominal pain, such as
	inflammatory bowel diseas	e, diabetes, unstable th	yroid disease
□ Yes □ No	Have history of abdominal	surgery (other than cho	lecystectomy or appendectom
□ Yes □ No	Are taking anticoagulants of	or antispasmodic, antidia	arrheal, or opioids or other pair
	-		ons for three consecutive days
	before each study visit		
□ Yes □ No	Are pregnant or lactating;	women of childbearing p	ootential complete a pregnancy
_ , , ,	test at each visit	-	
□ Yes □ No	Have known allergic reaction	ons to components of th	e ECG electrodes
□ Yes □ No			other intervention within 6
L res L NO	months of the date of cons		other meer control was a
			auld place the study participan
□ Yes □ No	at increased risk or preclud		ould place the study participan s full compliance with or
	completion of the study	se the study participant	o ran compnance with or
□ Yes □ No	Are unable to provide info	rmea consent	
For women only	<b>r</b>		
· · · · · · · · · · · · · · · · · · ·	omy: □ Yes □ No		nuse*: 🗆 Yes 🗅 No
(If no	to both of above)		efined as no menses for the
Preg	nancy test result:	· ·	cessation of menses is within 1 ct should be treated as pre-
_	/	1	ct snould be tredted as pre- gnancy test must be performed
🗆 Positive 🟚 Negative		michopausurunu u prej	grancy cost mast be perjointed.

2

Date:	/	/
	Date:	Date: /

The subject is eligible (mee	ets all of the incl	us on c	riteria and meets n	one of	f the exclusion criteria)
☑ True □ False					
<b>D</b>					
Procedure monitorin	g				
Subject has not taken medications affecting the gut or pain perception for 48 hours. (anticoagulants, antispasmodic, antidiarrheal, opioids)	Subject has no any food or d other than wa since 8 am	rink	TEA Methods: ST36-100Hz ST36-25Hz PC6-100Hz PC6-25Hz SM-25Hz		EKG Settings: Frequency and Amplification
<b>True</b> □ False	p True □ Fals	е	QU ST 36-1	100 HZ	Frequency: \(\int S\frac{1}{12}\) Amplification: \(\times\) \(\int \)
15 Minute Baseline E	KG without	<u>Stimu</u>	lation or Diste	ntior	1
15 Minute Baseline E  Time of Baseline Period St		<del>71 .</del>		ntior	1
	art:	2:0	11	ntior	1
Time of Baseline Period St	art:	2:0		ntior	1
Time of Baseline Period St	art: nd: lename:	1:0	11	ntior	1
Time of Baseline Period St Time of Baseline Period Er Baseline EKG Recording Fil Baseline Recording Folder	art: nd: lename: :	1:0 Z:	11 56 D-1	ntior	1
Time of Baseline Period St Time of Baseline Period Er Baseline EKG Recording Fil Baseline Recording Folder Rectal Distention One	art: ind: lename: :  without St Insertion:	1:0 Z:	11 56 D-1	ntior	1
Time of Baseline Period St Time of Baseline Period Er Baseline EKG Recording Fil Baseline Recording Folder	art: ind: lename: :  without St Insertion:	1:0 Z:	11 56 D-1 tion	ntior	1
Time of Baseline Period St Time of Baseline Period Er Baseline EKG Recording Fil Baseline Recording Folder  Rectal Distention One Time of Barostat Catheter	art:  d: lename: :  without St Insertion:	1:0 Z:	11 .56 D-1 tion	ntior	1
Time of Baseline Period St Time of Baseline Period Er Baseline EKG Recording Fil Baseline Recording Folder  Rectal Distention One Time of Barostat Catheter Time of Distention Initiation	art:  nd: lename: :  without St Insertion: on: ation:	1:0 Z:	11 56 D-1 tion 3:02 3:03	ntior	1

CRA Signature: \_\_\_\_\_\_ Date: \_\_\_/\_\_/\_\_

Rest Period	NA/	
Rest Period Start Time:		
Rest Period End Time:		

## 15 Minute Baseline EKG with Stimulation but no Rectal Distention

Time of Baseline Period Start:	3:12	
Time of Baseline Period End:	3:27	
Baseline EKG Recording Filename:	01-0-3	
Baseline EKG Recording Folder:		

## **TEA/Sham TEA Administration**

Time of TEA/Sham Initiation: 3:12 Time of change in output: 3:22 Time of change in output: Time of change in output:	Stimulation output (mA): 1.90 Stimulation output (mA): 2.26 Stimulation output (mA): Stimulation output (mA):
--	---

## **Rectal Distention Two with Stimulation**

Time of First Distention Initiation:	3:29	
Time of Last Distention Termination:	3:39	
Time of Barostat Catheter Removal:	3:39	
Distention EKG Recording Filename:	01-12-4	
Distention EKG Recording Folder:		

TRA Signature	Date:	/	1	

## HUM00189911 Optimization of TEA Modalities for Treatment of IBS-C

Name of Person who performed the procedure:
Signature of Person who performed the procedure:
Date: 8724721
PI Signature
Date: / /

HUM00189911 Optimization of TEA Modalities for Treatment of IBS-C  $^{\circ}$ 

**CUMULATIVE ADVERSE EVENTS** 

At end of study only: check this box if subject experienced NO ADVERSE EVENTS

· · · · · · · · · · · · · · · · · · ·					
Comments (include CRA dated initials for each event)					4 = resolved with sequelae 5 = fatal 6 = unknown
Med taken					4 = resolved v 5 = fatal 6 = unknown
əmoɔtuO				Outcome	ps
Reboued as					1 = resolved 2 = resolving 3 = not resolved
noitudinttA					3 2 7
Grade)					
Event End Date Severity	,	,			
Event Onset Date				Reported as SAE?	1 = yes 2 = no
Even				Agent	4 = probable 5 = definite
ption				Attribution: on to Study	
Adverse Event Description				Attribution: Relation to Study Agent	1 = unrelated 2 = unlikely 3 = possible
				Severity (Grade)	4 = life-threatening 5 = fatal
Adverse Event	Keported Date		,	Severi	1 = mild 2 = moderate 3 = severe

CRA Signature:

9